EVALUATION OF THE EFFECTIVENESS OF RUTAN IN THE COMPLEX THERAPY OF COVID-19 IN CHILDREN
Keywords:COVID-19, children 6-18 years old, Rutan 25 mg, antiviral efficacy
The global pandemic of coronavirus disease 2019 (COVID-19) presents an unprecedented challenge to public health, social and economic life [1, 2]. Despite the numerous drugs proposed for etiotropic treatment, there are currently no unequivocally proven effective drugs for adults and especially for children. The study is devoted to the study of the properties of the drug Rutan and the evaluation of its effectiveness in the complex therapy of COVID-19 in children aged 6-18 years.
The study included the study and analysis of the properties of the drug Rutan, its effectiveness in the complex therapy of COVID-19 in children aged 6-18 years. An open, controlled, comprehensive, randomized clinical laboratory study was conducted.
Clinical studies were conducted on 201 patients with mild and moderate forms of COVID-19 aged 6-18 years who were treated at the Zangiota 1 specialized clinic. Rutan 25 mg was used in the complex therapy of 101 children aged 6-18 with COVID-19. 100 patients who received only complex therapy served as a comparison group. It was found that Rutan 25 mg was well tolerated and harmless to patients, with no side effects. A pronounced clinical and significant antiviral effect was shown in patients with mild and moderate disease. After suffering COVID-19, in 30.7% of cases, post-covid symptoms are formed, mainly reflecting asthenic-vegetative, inflammatory-painful, catarrhal-respiratory manifestations within 4-6 months. In children treated with Rutan 25 mg, the frequency of post-covid manifestations was significantly less than in children in the control group (P<0.05).